Jaime Masjuan Selected Research

PF-05230907

1/2021

Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jaime Masjuan Research Topics

Disease

14	Stroke (Strokes) 01/2020 - 09/2008
10	Ischemic Stroke 06/2022 - 07/2011
4	Embolic Stroke 03/2021 - 10/2012
4	Multiple Sclerosis 01/2021 - 02/2003
4	Cerebral Hemorrhage 01/2021 - 01/2012
4	Hemorrhage 01/2019 - 01/2014
4	Atrial Fibrillation 01/2018 - 01/2012
3	Transient Ischemic Attack 09/2021 - 04/2012
2	Inflammation (Inflammations) 10/2022 - 01/2022
2	Brain Ischemia (Cerebral Ischemia) 06/2022 - 09/2021
2	Ischemia 02/2022 - 09/2021
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 04/2021 - 01/2021
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 09/2018 - 08/2017
2	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 07/2014 - 02/2008
1	Macrophage Activation Syndrome 10/2022
1	Infarction (Infarctions) 06/2022
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/2022
1	Chronic Progressive Multiple Sclerosis 01/2022
1	COVID-19 04/2021
1	Relapsing-Remitting Multiple Sclerosis 01/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2020
1	Corticobasal Degeneration 11/2019
1	Multiple System Atrophy 11/2019
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 11/2019
1	Thrombosis (Thrombus) 12/2017
1	Opsoclonus-Myoclonus Syndrome (Kinsbourne Syndrome) 07/2014
1	Nervous System Diseases (Neurological Disorders) 07/2014
1	Neurologic Manifestations (Neurological Manifestations) 02/2014
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 02/2014
1	Hematuria 01/2014
1	Metrorrhagia (Spotting) 01/2014
1	Dyslipidemias (Dyslipidemia) 01/2012
1	Hypertension (High Blood Pressure) 01/2012
1	Hematoma 10/2011
1	Seizures (Absence Seizure) 09/2011
1	Atherosclerosis 09/2011
1	Rupture 09/2011
1	Encephalitis (Encephalitis, Rasmussen) 01/2007
1	Teratoma (Teratoid Tumor) 01/2007
1	Neoplasms (Cancer) 01/2007
1	Progressive Multifocal Leukoencephalopathy 10/2005
1	Motor Neuron Disease (Primary Lateral Sclerosis) 04/2005
1	Central Nervous System Infections (Central Nervous System Infection) 04/2005
1	Demyelinating Diseases (Demyelinating Disease) 01/2005

Drug/Important Bio-Agent (IBA)

6	AnticoagulantsIBA 03/2021 - 01/2012
4	Dabigatran FDA Link 01/2019 - 07/2011
3	Biomarkers (Surrogate Marker)IBA 09/2021 - 11/2019
3	Vitamin K FDA Link 09/2018 - 01/2017
3	Warfarin (Coumadin)FDA LinkGeneric 08/2017 - 10/2012
3	AntibodiesIBA 07/2014 - 01/2007
3	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2012 - 09/2008
2	Glucose (Dextrose)FDA LinkGeneric 06/2022 - 01/2012
2	Pharmaceutical PreparationsIBA 06/2022 - 09/2011
2	Peptide Initiation Factors (Initiation Factor)IBA 02/2022 - 09/2021
2	Eukaryotic Initiation Factor-4EIBA 02/2022 - 09/2021
2	Immunoglobulin M (IgM)IBA 01/2021 - 02/2003
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020 - 01/2019
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 02/2008 - 01/2007
2	Oligoclonal BandsIBA 04/2005 - 01/2005
1	Interleukin-6 (Interleukin 6)IBA 10/2022
1	AntioxidantsIBA 06/2022
1	Oxygen (Dioxygen)IBA 06/2022
1	nitronesIBA 06/2022
1	Neuroprotective AgentsIBA 06/2022
1	ocrelizumabIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 09/2021
1	SteroidsIBA 04/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	PF-05230907IBA 01/2021
1	Alemtuzumab (Campath)FDA Link 01/2021
1	Ramipril (Altace)FDA LinkGeneric 01/2020
1	LipidsIBA 01/2020
1	Atorvastatin (Lipitor)FDA Link 01/2020
1	RivaroxabanIBA 01/2019
1	edoxabanIBA 08/2017
1	apixabanIBA 10/2012
1	Cytidine Diphosphate Choline (Citicoline)IBA 07/2012
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2012
1	Cocaine (Cocaine HCl)IBA 09/2011
1	A-factor (Streptomyces)IBA 08/2011
1	AutoantigensIBA 01/2007
1	Natalizumab (Tysabri)FDA Link 10/2005
1	Immunoglobulin G (IgG)IBA 04/2005

Therapy/Procedure

4	Therapeutics 03/2021 - 01/2012
3	Secondary Prevention 01/2020 - 10/2012
3	Thrombectomy 09/2018 - 02/2014
2	Artificial Respiration (Mechanical Ventilation) 04/2021 - 01/2021
2	Thrombolytic Therapy 10/2012 - 04/2012
2	Treatment Delay 01/2012 - 01/2012
1	Intravenous Administration 06/2022
1	Aftercare (After-Treatment) 09/2018
1	Patient Care 01/2018
1	Craniotomy 10/2011
1	Decompressive Craniectomy 10/2011
1	Immunotherapy 01/2007